Novan, Inc. is a pre-commercial pharmaceutical company focusing on dermatology and anti-infective therapies, with several clinical stage drug candidates for the treatment of viral, fungal, and inflammatory skin diseases. They are also developing products for the treatment of external genital warts, high-risk human papilloma virus (HPV), and SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd. and a strategic alliance with Orion Corporation, and was founded in 2006, headquartered in Durham, North Carolina.